Phase 3 N=61 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
Binge-Eating Disorder · Obesity
Primary: Binge-Eating Relapse — 3; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
Binge-Eating Disorder · Obesity
Primary: Change in Binge-Eating Frequency — -14; -17.00 episodes per past 28 days
Phase 3 N=447 The Late Presenter Treatment Optimisation Study
HIV/AIDS
Primary: Treatment Failure — 49; 70; 48; 69 Participants
Phase 3 N=1,721 A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
Non-Cystic Fibrosis Bronchiectasis
Primary: Annualized Rate of Pulmonary Exacerbations (PEs) — 1.015; 1.036; 1.286 exacerbation per participant-year — p==0.0019
Phase 3 N=30 Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
Bone Density, Low · Bone Loss · Anorexia Nervosa
Primary: Percent Change From Baseline to 12 Months in Postero-anterior Lumbar Spine Bone Mineral Density by Dual Energy X-ray Absorptiometry (DXA). — 12.4; -0.3 % change…
Phase 3 N=52 Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
Paroxysmal Nocturnal Hemoglobinuria
Primary: Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority — 2.01 g/dL — p=<0.0001
Phase 3 N=1,899 Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
COVID-19
Primary: Groups 2a and 2b and ARCT-154-J01 Historical Control: Geometric Mean Titers (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody…
Phase 3 N=611 Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
Schizophrenia
Primary: Change From Baseline in the Overall Composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive…
Phase 3 N=298 Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
Asthma
Primary: Proportion of the Participants Who Discontinued OCS Without Loss of Asthma Control at Week 28 and Week 52 — 32.2; 50.3 Percentage of participants
Phase 3 N=585 A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
Extensive Stage Small Cell Lung Cancer
Primary: OS — 15.77; 11.10 month — p=<0.001
Phase 3 N=301 A Extension Study of Udenafil in Adolescents
Functional Single Ventricle Heart Disease
Primary: Treatment-Emergent Adverse Events — 257; 206; 31; 54 Participants
Phase 3 N=25 Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
Atypical Hemolytic Uremic
Primary: Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response — 64.0 percentage of participants
Phase 3 N=126 Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)
Type 2 Spinal Muscular Atrophy
Primary: Change From Baseline at the End of Period 1 in the Hammersmith Functional Motor Scale Expanded - Total Score - in the ≥ 2 to < 18 Years Age Group — 2.39; 0.51 Scores on…
Phase 3 N=886 Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep®
Elective Colonoscopy
Primary: Phase II - Dose Finding: Proportion of Patients With Adequate Bowel Cleansing — 0.75; 0.94; 0.94 Proportion of patients
Phase 3 N=304 Efficacy and Safety of Mexidol® in Stroke Therapy
Ischemic Stroke
Primary: Change From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy — -2.45; -2.01 score on a scale